The Effect of Acth on Plasma Testosterone and Androstenedione Concentrations in Patients With Prostatic Carcinoma

Cowley, T.; Brownsey, Brian G.; Harper, M. E.; Peeling, W. B.; Griffiths, K.

doi:10.1530/acta.0.0810310

Cited by 23 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The testosterone concentrations in the pe ripheral plasma of patients with carcinoma of the prostate reported here are in agreement with the data contained in the literature 0Gandy and Peterson, 1968;Sciarra et al, 1973;Cowley et al, 1976;Harper et al, 1976) and indicate that Leydig cell function in these patients is within the normal range of old men. All the patients with varicocele studied here and those reported on in the literature (Comhaire and Vermeulen, 1975;Swerdloff and Walsh, 1975) had normal plasma testoster one values.…”

Section: Discussionsupporting

confidence: 92%

Testosterone and Testosterone Precursors in the Spermatic Vein and in the Testicular Tissue of Old Men

Pirke¹,

Sintermann²,

Vogt³

1980

Gerontology

View full text Add to dashboard Cite

Testosterone and the testosterone precursors pregnenolone, progesterone, 17α-hydroxyprogesterone, 17α-hydroxypregnenolone, androstenedione, androstenediol and deny droepiandrosterone were measured in the spermatic vein plasma and in the testicular tissue of young and old men. Testosterone and its precursors decreased in the testicular tissue of old men. However, progesterone and 17α-hydroxyprogesterone increased in relation to testosterone in the testicular tissue and in the spermatic vein of old men. It is assumed that these age-dependent changes are caused by an impaired oxygen supply of the ageing testes. This hypothesis is supported by the observation that the same changes in steroid pattern seen in old age can be observed under reduced oxygen supply in in vitro incubation experiments with testicular tissue.

show abstract

Section: Discussionsupporting

confidence: 92%

Testosterone and Testosterone Precursors in the Spermatic Vein and in the Testicular Tissue of Old Men

Pirke¹,

Sintermann²,

Vogt³

1980

Gerontology

View full text Add to dashboard Cite

show abstract

“…So far, however, initial hormonal therapy in prostatic cancer has been only partial and limited to removal of the androgens of testicular origin. Since 5% to 10% of circulating androgens are of adrenal original, it is most likely that they continue to have a stimulatory effect on the growth of prostatic cancer after removal of testicular androgens [19][20][21][22].…”

Section: Introductionmentioning

confidence: 99%

New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens

et al. 1983

View full text Add to dashboard Cite

To completely eliminate androgens of both testicular and adrenal origin, 37 previously untreated patients with advanced (stages C or D) prostatic cancer received the combination therapy using an LHRH agonist (HOE-766) and a pure antiandrogen (RU-23908). The response criteria developed by the National Prostatic Cancer Project were used. A positive response (assessed by bone scan and/or serum prostatic acid phosphatase measured by radioimmunoassay was observed in 29 of the 30 cases who could be evaluated by these objective criteria (97%). The objective response was parallel to a rapid and marked improvement of the clinical signs and symptoms related to prostate cancer (prostatism, bone pain, and general well being). In marked contrast, the same combination therapy applied to patients previously treated with high doses of diethylstilbestrol (13 patients) showed a positive objective response in only 55% of cases. In 23 previously castrated patients showing relapse, an objective response was seen in only 25% of cases after neutralization of adrenal androgens by the antiandrogen. Previous treatment with chlorotrianisene (TACE) had no detectable effect on prostatic cancer and patients having previously received such treatment had a rate of positive response similar to previously untreated patients (five of five). In the previously untreated patients receiving the combination therapy, a 60% fall in serum prostatic acid phosphatase was observed as early as five days after starting treatment, at a time when the serum androgen concentration was 100% to 200% above control. Combined treatment with the pure antiandrogen completely prevents flare-up of the disease, a complication previously found in a significant proportion of patients treated with an LHRH agonist alone. The present data show that complete withdrawal of androgens by combined hormonal therapy with the LHRH agonist (or castration) and a pure antiandrogen leads to a positive objective response in more than 95% of cases as opposed to 60%-70% as reported by many groups using the previous partial hormonal therapy (castration or high doses of estrogens). Adrenal androgens are most likely responsible for this difference. The present study also shows that the proportion of androgen-sensitive cells decreases from more than 95% in untreated patients to 25% to 55% after previous partial hormonal therapy. Such data clearly indicate that the previous partial hormonal therapy exclusively aimed at neutralizing testicular androgens left 25% to 55% of cancer cells having a relatively low sensitivity to androgens in a hormonal milieu compatible with their continuous growth. No clinical or biochemical side effect could be detected except those related to reduced serum androgen levels.(ABSTRACT TRUNCATED AT 400 WORDS)

show abstract

“…'Residual' testosterone in the plasma of castrated pa tients, or those on DES or Zoladex, is of adrenal origin [7,23], although relapse or disease progression is rarely associated with a secondary rise in testosterone levels [24]. Adrenal Cm-steroids, dehydroepiandrosterone (DHA) sulphate, DHA and androstenedionc would seem to be metabolised peripherally to produce testoster one and are also utilised by the human prostate ( fig.…”

Section: Endocrine Treatmentsmentioning

confidence: 99%

Prostatic Cancer: Aetiology and Endocrinology

Griffiths

Eaton²,

Davies³

1989

Horm Res

Self Cite

View full text Add to dashboard Cite

show abstract

The Effect of Acth on Plasma Testosterone and Androstenedione Concentrations in Patients With Prostatic Carcinoma

Cited by 23 publications

References 0 publications

Testosterone and Testosterone Precursors in the Spermatic Vein and in the Testicular Tissue of Old Men

Testosterone and Testosterone Precursors in the Spermatic Vein and in the Testicular Tissue of Old Men

New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens

Prostatic Cancer: Aetiology and Endocrinology

Contact Info

Product

Resources

About